Daraxonrasib, a new pancreatic cancer drug, cut the risk of death by 60% in a Phase 3 trial. A doctor explains how it works, ...
New experimental medications seem to extend survival with the hard-to-treat cancer.
Revolution Medicines shared Phase III clinical trial results for a pill called daraxonrasib in patients with previously ...
Revolution Medicines' drug for pancreatic cancer succeeded in a highly anticipated Phase 3 trial, the company said.
As we age, our cells accumulate genetic changes—mutations—some of which open the door to cancer. Scientists call these ...
The overall risk of malignancy in pancreatic cysts may be as low as 0.5 to 1.5%, and the annual risk of progression is 0.5%. 7,15 Conversely, studies estimate that 15% of all pancreatic ...
Several factors can influence a person’s life expectancy if they experience recurrence of pancreatic cancer, including the location of recurrence, a person’s treatment, and their tumor grading, size, ...
They’re easy to mistake for other conditions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results